Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients

It has been suggested that low-level viremia or blips in HIV-infected patients on antiretroviral treatment are related to assay variation and/or increased sensitivity of new commercial assays. The 50-copy cut-off for virologic failure is, therefore, under debate. Treated patients with low-level vire...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2014-10, Vol.9 (10), p.e110749-e110749
Hauptverfasser:	Hofstra, Laura Marije, Mudrikova, Tania, Stam, Arjen J, Otto, Sigrid, Tesselaar, Kiki, Nijhuis, Monique, Wensing, Annemarie M J
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adult AIDS Anti-Retroviral Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Assaying Biology and life sciences Failure Female HIV HIV Infections - blood HIV Infections - complications HIV Infections - drug therapy HIV-1 - genetics Human immunodeficiency virus Humans Level (quantity) Male Medicine and health sciences Middle Aged Patients Protease inhibitors Ribonucleic acid RNA RNA, Viral - analysis Viral Load Viremia Viremia - virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	It has been suggested that low-level viremia or blips in HIV-infected patients on antiretroviral treatment are related to assay variation and/or increased sensitivity of new commercial assays. The 50-copy cut-off for virologic failure is, therefore, under debate. Treated patients with low-level viremia (persistent viral loads (VL) of 50-1000 copies/mL, group A, N = 16) or a blip (single detectable VL, group B, N = 77) were compared to a control group (consistently suppressed viremia since start therapy (1000 copies/mL that was not followed by a VL
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0110749